Mirum Pharmaceuticals: Q4 Earnings Insights
Portfolio Pulse from Benzinga Insights
Mirum Pharmaceuticals (NASDAQ:MIRM) reported Q4 earnings with an EPS of $-0.66, missing estimates by -175.0% against an expected $-0.24. Revenue increased by $41.65 million from the previous year. Despite this miss, past performance shows a positive trend in beating revenue estimates and a mixed EPS performance.
February 28, 2024 | 9:40 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Mirum Pharmaceuticals reported a significant miss in Q4 earnings with an EPS of $-0.66, far below the expected $-0.24, but showed a strong increase in revenue year-over-year.
The significant miss in EPS is likely to negatively impact investor sentiment in the short term, despite the increase in revenue. Historical data shows that past earnings performance, especially unexpected misses, can lead to volatility in stock prices. However, the consistent increase in revenue might mitigate some negative sentiment.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100